Search Results
10
Everything
Search Filters
Organization
C4 Therapeutics, Inc.
C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
February 27, 2025 07:00 ET
|
C4 Therapeutics, Inc.
Planning Activities Are Ongoing for Next Phase of Cemsidomide Clinical Development in Multiple Myeloma and Non-Hodgkin’s Lymphoma; Trials Expected to Initiate in Early 2026 CFT1946 Phase 1/2 Trial...
C4 Therapeutics to Participate in Upcoming March Investor Conferences
February 24, 2025 07:00 ET
|
C4 Therapeutics, Inc.
WATERTOWN, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation...
C4 Therapeutics Announces 2025 Milestones Across Clinical Portfolio of Degrader Medicines Pursuing Targets of High Unmet Need in Oncology
January 14, 2025 07:00 ET
|
C4 Therapeutics, Inc.
Cemsidomide Data Presented at American Society of Hematology (ASH) Annual Meeting Support Best-in-Class Profile; Program Advancing to Next Phase of Clinical Development in Multiple Myeloma and...
C4 Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 08, 2025 07:00 ET
|
C4 Therapeutics, Inc.
WATERTOWN, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation...
C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader
December 08, 2024 12:30 ET
|
C4 Therapeutics, Inc.
In Multiple Myeloma, Cemsidomide in Combination with Dexamethasone at Highest Dose Level Explored to Date Achieved 36 Percent Overall Response Rate (ORR) and 45 Percent Clinical Benefit Rate (CBR);...
C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors
November 20, 2024 07:00 ET
|
C4 Therapeutics, Inc.
Hoerter Brings Over Three Decades of Oncology Commercialization and Leadership Experience Appointment Underscores Continued Transformation of Board to Lead C4T into Next Phase of Pipeline...
C4 Therapeutics Announces First Patient Dosed in CFT8919 Clinical Trial
November 06, 2024 07:00 ET
|
C4 Therapeutics, Inc.
WATERTOWN, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation...
C4 Therapeutics to Present Data from the Ongoing Phase 1/2 Trial of Cemsidomide in Multiple Myeloma and Non-Hodgkin’s Lymphoma at the American Society of Hematology (ASH) Annual Meeting
November 05, 2024 09:00 ET
|
C4 Therapeutics, Inc.
WATERTOWN, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation...
C4 Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
October 31, 2024 07:00 ET
|
C4 Therapeutics, Inc.
Cemsidomide Phase 1/2 Trial in Multiple Myeloma and non-Hodgkin’s Lymphoma Continues to Progress: Data from Both Indications to be Presented at the 66th American Society of Hematology (ASH) Annual...
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
October 28, 2024 16:01 ET
|
C4 Therapeutics, Inc.
WATERTOWN, Mass., Oct. 28, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation...